[Fundamental and clinical studies of cefpimizole in the field of obstetric and gynecologic infections].
We made fundamental and clinical studies of a new cephalosporin derivative cefpimizole (AC-1370), and found the following. In 7 patients treated with AC-1370 for the fundamental study of the drug, the blood level of the drug in the uterine artery scarcely differed from that in the elbow vein, and it decreased steadily with time. It remained to be 6.5 approximately 7.0 micrograms/ml 5 hours after intravenous injection of 1 g of the drug. The tissue-serum concentration ratio of the drug was 122 approximately 58% in the portio vaginalis where the drug was transferred at the highest level, and 56 approximately 114% in the oviduct where it was transferred at the lowest level; the mean level was 61.5%. The responses to AC-1370 of 10 patients with genital infections were excellent in 1, good in 8 and poor in the other, with a response rate of 90%. Bacteriologically, pathogens were eradicated in 3, decreased in 2, and the response was unknown in the other 5. No side effects or abnormal laboratory findings were noted except for leukopenia in 1 patient.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged
D002511:Cephalosporins; C038845:cefpimizole